NCT06656234View on ClinicalTrials.gov

The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

September 15, 2027

Study Completion Date

September 15, 2028

Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
DRUG

Glofitamab

Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling.

DRUG

Obinutuzumab

Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.

Trial Locations (1)

200025

Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT06656234 - The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study | Biotech Hunter | Biotech Hunter